Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector

Sandeep K. Tripathy, Eric C. Svensson, Hugh B Black, Eugene Goldwasser, Michal Margalith, Peter M. Hobart, Jeffrey M. Leiden

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

Erythropoietin (Epo)-responsive anemia is a common and debilitating complication of chronic renal failure and human immunodeficiency virus infection. Current therapy for this condition involves repeated intravenous or subcutaneous injections of recombinant of recombinant Epo. In this report, we describe the development of a novel muscle-based gene transfer approach that produces long-term expression of physiologically significant levels of Epo in the systemic circulation of mice. We have constructed a plasmid expression vector, pVRmEpo, that contains the murine Epo cDNA under the transcriptional control of the cytomegalovirus immediate early (CMV-IE) promoter, the CMV-IE 5' untranslated region, and intron A. A single intramuscular (i.m.) injection of as little as 10 μg of this plasmid into immunocompetent adult mice produced physiologically significant elevations is serum Epo levels and increased hematocrits form preinjection levels of 48 ± 0.4% to levels of 64 ± 3.3% 45 days after injection. Hematocrits in these animals remained elevated at greater than 60% for at least 90 days after a single i.m. injection of 10 μg of pVRmEpo. We observed a dose-response relationship between the amount of plasmid DNA injected and subsequent elevations in hematocrits. Mice injected once with 300 μg of pVRmEpo displays 5-fold increased serum Epo levels and elevated hematocrits of 79 ± 3.3% at 45 days after injection. The i.m. injected of plasmid DNA represents a viable nonviral gene transfer method for the treatment of acquired and inherited serum protein deficiencies.

Original languageEnglish (US)
Pages (from-to)10876-10880
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume93
Issue number20
DOIs
StatePublished - Oct 1 1996
Externally publishedYes

Fingerprint

Intramuscular Injections
Erythropoietin
Plasmids
Hematocrit
DNA
Cytomegalovirus
Protein Deficiency
Injections
5' Untranslated Regions
Virus Diseases
Subcutaneous Injections
Serum
Intravenous Injections
Introns
Genes
Chronic Kidney Failure
Anemia
Blood Proteins
Complementary DNA
HIV

Keywords

  • anemia
  • gene therapy
  • serum protein
  • skeletal muscle

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. / Tripathy, Sandeep K.; Svensson, Eric C.; Black, Hugh B; Goldwasser, Eugene; Margalith, Michal; Hobart, Peter M.; Leiden, Jeffrey M.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, No. 20, 01.10.1996, p. 10876-10880.

Research output: Contribution to journalArticle

Tripathy, Sandeep K. ; Svensson, Eric C. ; Black, Hugh B ; Goldwasser, Eugene ; Margalith, Michal ; Hobart, Peter M. ; Leiden, Jeffrey M. / Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. In: Proceedings of the National Academy of Sciences of the United States of America. 1996 ; Vol. 93, No. 20. pp. 10876-10880.
@article{5c27dab5ac32412dbfffeeb0e21cebba,
title = "Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector",
abstract = "Erythropoietin (Epo)-responsive anemia is a common and debilitating complication of chronic renal failure and human immunodeficiency virus infection. Current therapy for this condition involves repeated intravenous or subcutaneous injections of recombinant of recombinant Epo. In this report, we describe the development of a novel muscle-based gene transfer approach that produces long-term expression of physiologically significant levels of Epo in the systemic circulation of mice. We have constructed a plasmid expression vector, pVRmEpo, that contains the murine Epo cDNA under the transcriptional control of the cytomegalovirus immediate early (CMV-IE) promoter, the CMV-IE 5' untranslated region, and intron A. A single intramuscular (i.m.) injection of as little as 10 μg of this plasmid into immunocompetent adult mice produced physiologically significant elevations is serum Epo levels and increased hematocrits form preinjection levels of 48 ± 0.4{\%} to levels of 64 ± 3.3{\%} 45 days after injection. Hematocrits in these animals remained elevated at greater than 60{\%} for at least 90 days after a single i.m. injection of 10 μg of pVRmEpo. We observed a dose-response relationship between the amount of plasmid DNA injected and subsequent elevations in hematocrits. Mice injected once with 300 μg of pVRmEpo displays 5-fold increased serum Epo levels and elevated hematocrits of 79 ± 3.3{\%} at 45 days after injection. The i.m. injected of plasmid DNA represents a viable nonviral gene transfer method for the treatment of acquired and inherited serum protein deficiencies.",
keywords = "anemia, gene therapy, serum protein, skeletal muscle",
author = "Tripathy, {Sandeep K.} and Svensson, {Eric C.} and Black, {Hugh B} and Eugene Goldwasser and Michal Margalith and Hobart, {Peter M.} and Leiden, {Jeffrey M.}",
year = "1996",
month = "10",
day = "1",
doi = "10.1073/pnas.93.20.10876",
language = "English (US)",
volume = "93",
pages = "10876--10880",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "20",

}

TY - JOUR

T1 - Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector

AU - Tripathy, Sandeep K.

AU - Svensson, Eric C.

AU - Black, Hugh B

AU - Goldwasser, Eugene

AU - Margalith, Michal

AU - Hobart, Peter M.

AU - Leiden, Jeffrey M.

PY - 1996/10/1

Y1 - 1996/10/1

N2 - Erythropoietin (Epo)-responsive anemia is a common and debilitating complication of chronic renal failure and human immunodeficiency virus infection. Current therapy for this condition involves repeated intravenous or subcutaneous injections of recombinant of recombinant Epo. In this report, we describe the development of a novel muscle-based gene transfer approach that produces long-term expression of physiologically significant levels of Epo in the systemic circulation of mice. We have constructed a plasmid expression vector, pVRmEpo, that contains the murine Epo cDNA under the transcriptional control of the cytomegalovirus immediate early (CMV-IE) promoter, the CMV-IE 5' untranslated region, and intron A. A single intramuscular (i.m.) injection of as little as 10 μg of this plasmid into immunocompetent adult mice produced physiologically significant elevations is serum Epo levels and increased hematocrits form preinjection levels of 48 ± 0.4% to levels of 64 ± 3.3% 45 days after injection. Hematocrits in these animals remained elevated at greater than 60% for at least 90 days after a single i.m. injection of 10 μg of pVRmEpo. We observed a dose-response relationship between the amount of plasmid DNA injected and subsequent elevations in hematocrits. Mice injected once with 300 μg of pVRmEpo displays 5-fold increased serum Epo levels and elevated hematocrits of 79 ± 3.3% at 45 days after injection. The i.m. injected of plasmid DNA represents a viable nonviral gene transfer method for the treatment of acquired and inherited serum protein deficiencies.

AB - Erythropoietin (Epo)-responsive anemia is a common and debilitating complication of chronic renal failure and human immunodeficiency virus infection. Current therapy for this condition involves repeated intravenous or subcutaneous injections of recombinant of recombinant Epo. In this report, we describe the development of a novel muscle-based gene transfer approach that produces long-term expression of physiologically significant levels of Epo in the systemic circulation of mice. We have constructed a plasmid expression vector, pVRmEpo, that contains the murine Epo cDNA under the transcriptional control of the cytomegalovirus immediate early (CMV-IE) promoter, the CMV-IE 5' untranslated region, and intron A. A single intramuscular (i.m.) injection of as little as 10 μg of this plasmid into immunocompetent adult mice produced physiologically significant elevations is serum Epo levels and increased hematocrits form preinjection levels of 48 ± 0.4% to levels of 64 ± 3.3% 45 days after injection. Hematocrits in these animals remained elevated at greater than 60% for at least 90 days after a single i.m. injection of 10 μg of pVRmEpo. We observed a dose-response relationship between the amount of plasmid DNA injected and subsequent elevations in hematocrits. Mice injected once with 300 μg of pVRmEpo displays 5-fold increased serum Epo levels and elevated hematocrits of 79 ± 3.3% at 45 days after injection. The i.m. injected of plasmid DNA represents a viable nonviral gene transfer method for the treatment of acquired and inherited serum protein deficiencies.

KW - anemia

KW - gene therapy

KW - serum protein

KW - skeletal muscle

UR - http://www.scopus.com/inward/record.url?scp=0029744337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029744337&partnerID=8YFLogxK

U2 - 10.1073/pnas.93.20.10876

DO - 10.1073/pnas.93.20.10876

M3 - Article

C2 - 8855275

AN - SCOPUS:0029744337

VL - 93

SP - 10876

EP - 10880

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 20

ER -